CY2027: your surgeons take 7%, your facility gets 2.4%.

Two CMS proposed rules landed in July, a week apart, and they should be read as one document. The physician fee schedule (CMS-1848-P) proposes RVU changes that cut aggregate orthopedic surgery payment by roughly 7%*. The companion outpatient rule (CMS-1850-P) proposes a +2.4%* update to hospital outpatient and ASC facility payment. Same agency. Same year. Same episode. Opposite directions.

That is not an accident, and it is not a one-year event. It is the structure.

Why the asymmetry is permanent unless Congress acts

Facility payment updates are tied by statute to a market-basket inflation measure. Physician payment is tied to no inflation measure at all. Every year that arrangement persists, the professional share of the same episode shrinks automatically — no policy decision required, no announcement made. Layer the CY2027 conversion factors on top (roughly $33.17* for qualifying APM participants and $32.84* for everyone else, both down) and the specialty-level estimate lands near 8–9%* all-in.

The loop that generated the cut — and will generate the next one

The joint-replacement reductions came from what CMS calls a site-of-service anomaly: these procedures moved outpatient, but their 90-day global valuations still assumed inpatient visits. So CMS proposes work-RVU cuts to TKA (27447), THA (27130), and shoulder arthroplasty (23470 / 23472) — landing near ~20% on hip and knee replacement specifically, roughly triple the ~7% specialty average, and below even the RUC’s already-reduced recommendations. That gap is the whole point of the line below: the codes that define your service line are cut far deeper than the headline number suggests.

Read the mechanism, not just the number: remove codes from the inpatient-only list → volume shifts outpatient → claims data show it → the anomaly screen fires → the work RVU gets cut. The inpatient-only list disappears entirely by 2029, and CY2027 proposes adding 618* more codes to the ASC covered list. The efficiency your teams created is being repriced out of the professional fee — and spine, foot & ankle, and upper extremity are the obvious next codes through the same screen.

Four more things in the rules that hit your P&L

• Same-day E/M at 50%. An office visit reported with modifier 25 alongside a procedure with a 0-, 10-, or 90-day global would be paid at 50%* — even when properly documented as significant and separately identifiable. Documentation does not prevent it. Quantify how often this pattern appears in your book.
• Practice-expense reform. The indirect practice cost index gets phased out for a capped “PE stabilizer.” A buried comment solicitation asks whether facility-based indirect PE should drop from 50% to “such as 0 percent” — a signal worth reading if your surgeons are hospital-employed.
• RTM gets detonated for vendor models. Remote therapeutic monitoring would require established patients, initiation at a face-to-face visit, and clinical staff who are direct employees — contracted third-party staff would not qualify. Device codes get revalued down; 17 codes may collapse to 4 bundled G-codes. CPT 98985 is named. If a vendor runs your RTM program with its own staff, that billing model may not survive. Re-read the contract now, not in December.
• ASM starts January 1, 2027. Mandatory, five years, selected low-back-pain clinicians scored at the individual TIN/NPI level, with ±9%* of Part B two years later rising toward ±12%*. Plus a lumbar-MRI overuse measure and a PRO submission incentive. The ASM math is no longer hypothetical.

The signal underneath the numbers

CMS is engineering a shift toward longitudinal, outcomes-based payment with primary care at the center — the G2211 complexity add-on becomes a 16%* modifier on the E/M base, and a second modifier worth 32%* is reserved for clinicians providing longitudinal care inside an ACO. Primary care gets new upside. Specialists get RVU cuts, global-period scrutiny, and a mandatory two-sided-risk model. That is a closed system rebalancing, and the specialty side is funding it — the longer arc is in the big cycle.

And PROMs stopped being registry hygiene. The joint MVP’s core measures now include functional status after knee replacement (Q470) and risk-standardized complication rate (Q480), with traditional MIPS ending after 2028 and MVP reporting mandatory from 2029. The centers already collecting patient-reported outcomes are about to look very different from the ones that aren’t.

What to do in the next sixty days

• Model it code by code, not by the specialty average. Use your trailing-12 utilization and the proposed values for 27447, 27130, 23470/23472, with the correct conversion factor. A wRVU-based compensation formula can transmit a Medicare cut into an all-payer pay cut — check the contract language before it does.
• Audit modifier 25. Measure the revenue at risk under a 50% reduction and document why those same-day services occur.
• Re-underwrite every RTM contract against the direct-employee requirement.
• Instrument outcomes now. PROs and complication capture are the currency of ASM, MVP, and whatever bundled model follows surgery into the ASC. Build it before you’re scored on it, not after — that’s the difference between holding risk and merely bearing it.
• Comment. OPPS/ASC (CMS-1850-P) closes August 31, 2026; the fee schedule (CMS-1848-P) closes September 14, 2026. The comments that move CMS carry code-specific time data, post-op utilization, real practice-expense figures, and workable alternatives — not objections to the size of the cut.

None of this means outpatient migration was a mistake. Shorter stays and modern recovery protocols are real, and the people reading this built them. It means the savings those gains created are being harvested from the professional fee while the facility side receives an inflation-linked raise. Knowing which side of that line you’re standing on is now a strategic decision rather than an accident of history.

All CY2027 figures are from CMS proposed rules (CMS-1848-P, CMS-1850-P, July 2026) and may change in the final rules; Congress may also alter the statutory update. Figures marked * are illustrative or program-dependent. Not clinical, legal, or financial advice. MSKvalue assembles independent best-of-class products with the American Joint Replacement Registry as the outcomes backbone.